The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Elin Edda Sigurdardottir; Ingemar Turesson; Sigrun Helga Lund; Ebba K Lindqvist; Sham Mailankody; Neha Korde; Magnus Björkholm; Ola Landgren; Sigurdur Y Kristinsson

doi:10.1001/jamaoncol.2015.23

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Elin Edda Sigurdardottir, Ingemar Turesson, Sigrun Helga Lund, Ebba K Lindqvist, Sham Mailankody, Neha Korde, Magnus Björkholm, Ola Landgren, Sigurdur Y Kristinsson

Division of Hematology and Transfusion Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.

Original language	English
Pages (from-to)	168-174
Journal	JAMA Oncology
Volume	1
Issue number	2
DOIs	https://doi.org/10.1001/jamaoncol.2015.23
Publication status	Published - 2015

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/jamaoncol.2015.23

http://www.ncbi.nlm.nih.gov/pubmed/26181017?dopt=Abstract

Cite this

@article{fd1a312a465044809e3a649fe2248e00,

title = "The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.",

abstract = "Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.",

author = "Sigurdardottir, {Elin Edda} and Ingemar Turesson and Lund, {Sigrun Helga} and Lindqvist, {Ebba K} and Sham Mailankody and Neha Korde and Magnus Bj{\"o}rkholm and Ola Landgren and Kristinsson, {Sigurdur Y}",

year = "2015",

doi = "10.1001/jamaoncol.2015.23",

language = "English",

volume = "1",

pages = "168--174",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

AU - Sigurdardottir, Elin Edda

AU - Turesson, Ingemar

AU - Lund, Sigrun Helga

AU - Lindqvist, Ebba K

AU - Mailankody, Sham

AU - Korde, Neha

AU - Björkholm, Magnus

AU - Landgren, Ola

AU - Kristinsson, Sigurdur Y

PY - 2015

Y1 - 2015

N2 - Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.

AB - Multiple myeloma (MM) is consistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS). The average annual risk of progression from MGUS to multiple myeloma is 0.5% to 1.0%. Current guidelines suggest life-long clinical follow-up of individuals diagnosed as having MGUS depending on risk stratification. The impact of diagnosing and conducting clinical follow-up of MGUS on MM survival is unclear.

U2 - 10.1001/jamaoncol.2015.23

DO - 10.1001/jamaoncol.2015.23

M3 - Article

C2 - 26181017

SN - 2374-2437

VL - 1

SP - 168

EP - 174

JO - JAMA Oncology

JF - JAMA Oncology

IS - 2

ER -

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this